A study funded in part by the National Institutes of Health (NIH) has revealed important insights into the genetics of deposits in the eye, known as reticular pseudodrusen (RPD), that are linked to ...
A study funded in part by the National Institutes of Health (NIH) has revealed important insights into the genetics of deposits in the eye, known as reticular pseudodrusen (RPD), that are linked to ...
Apellis Pharmaceuticals, Inc. ( APLS) Citi Annual Global Healthcare Conference 2025 December 2, 2025 2:30 PM EST ...
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) is one of the best upside stocks to buy now. On November 12, Apellis ...
The complement system, a cornerstone of the innate immune system, is a complex network of proteins that work in concert to detect and eliminate threats. It operates through three primary pathways: the ...
FDA approval enables Complement Therapeutics to start the Opti-GAIN phase 1/2 trial for CTx001 in GA secondary to AMD. CTx001 is an AAV-based gene therapy delivering a truncated Complement Receptor 1 ...
ANX007 targets C1q to inhibit the complement cascade, reducing neuroinflammation and protecting photoreceptors in AMD and GA. The ARCHER trial showed significant vision loss reduction, with a 73% risk ...
The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...
Panelists discuss how targeted therapies for immunoglobulin A (IgA) nephropathy are advancing rapidly, with promising results from trials of B-cell modulating agents that inhibit APRIL/BAFF signaling ...
ABSTRACT: The concept of neuroimmune interactions has shown significant advancements over the years. Modern research has revealed many areas of connection between fields, which were previously viewed ...
Mass General Brigham researchers found granzyme K (GZMK) drives inflammation in autoimmune diseases, opening new possibilities for targeted treatments. Researchers at Mass General Brigham have made a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback